Actinogen Medical Limited (ASX:ACW)

Australia flag Australia · Delayed Price · Currency is AUD
0.0460
+0.0060 (15.00%)
Apr 20, 2026, 3:49 PM AEST
Market Cap168.80M +56.3%
Revenue (ttm)7.36M -18.4%
Net Income-17.91M
EPS-0.01
Shares Out3.59B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,183,985
Average Volume2,890,931
Open0.0410
Previous Close0.0400
Day's Range0.0410 - 0.0470
52-Week Range0.0190 - 0.0720
Beta1.00
RSI68.00
Earnings DateMay 26, 2026

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange Australian Securities Exchange
Ticker Symbol ACW
Full Company Profile

Financial Performance

In fiscal year 2025, Actinogen Medical's revenue was 5.49 million, a decrease of -44.73% compared to the previous year's 9.93 million. Losses were -14.73 million, 12.9% more than in 2024.

Financial Statements